Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Requirements For Next Round Of COVID Vaccines Unclear

Executive Summary

Peter Marks tells the Pink Sheet that FDA isn’t ready to say when Americans might need additional COVID shots or what data would be required of sponsors. It’s just one of the ways the country isn’t as close to achieving a flu vaccine-like strategy for COVID as the Biden administration suggests.

You may also be interested in...



COVID Vaccines: XBB Strain Easy Call, But Disagreements Abound Between FDA, Advisors On Logistics

It took little convincing for FDA advisors to support changing COVID-19 vaccines to monovalent XBB formulations, but the committee still isn’t sold on the agency’s annual influenza-like campaign strategy for COVID vaccines and raised several harder calls that FDA and CDC will need to make including when to cut off bivalent shots use and who should get XBB.

ACIP Backs Transition To Bivalent COVID-19 Vaccine, Flexibility On Number Of Annual Doses

The CDC panel supports transition away from the monovalent vaccine to simplify the schedule and reduce errors, but says more data is needed. Members disagree on whether children will need a primary series and favor the option for older adults and the immunocompromised to be vaccinated twice a year.

Ivermectin Settlement Brings Relief And Worry For US FDA Communications

The FDA’s decision to end litigation challenging an agency communication that tried to tackle COVID-19 misinformation leaves an appeals court opinion in place that could haunt it later. But continuing to fight the case could have left the agency in a far worse position.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel